Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MCRB)

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Business Wire April 9, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 28, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 19, 2024

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Business Wire February 28, 2024

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Business Wire February 27, 2024

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Business Wire February 26, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 17, 2024

Seres Therapeutics Announces VOWST(TM) Commercial Launch Update and US FDA Fast Track Designation for SER-155

Business Wire January 9, 2024

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2024
View More News ››

Opinion & Analysis (NDAQ:MCRB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MCRB)

RE:Now it's time to accumulate @78 cents

Q4 earnings says as a result, we have confidence that we will ultimately achieve our goal of VOWST becoming a foundational therapy...
Napcoo - March 28, 2024

Now it's time to accumulate @78 cents

$225 mln due if target milestone reached for the $575 mln deal, $175 mln upfront, $125 mln FDA approved, latest updates to reach sales...
Napcoo - March 28, 2024

Price

In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will...
IvanIvan - April 27, 2023

Maybe a chance to accumulate

Below 5 again. Maybe right cap on approval is between 800 - 900 million? 
hoffbag - January 15, 2023

Popping now!

Target valuation getting closer. 
hoffbag - October 31, 2022

Patience cont….

Now over 6. 
hoffbag - September 8, 2022
View more Bullboard ››

Enerev5 Metals Inc

Enerev5 Metals Inc

Enerev5 Metals Inc. is a Canadian resource company. The Company is focused on the exploration and development potential ...
View More »